speb/financial-data huggingface dataset:
CDNA cash_flow (annual, 2023-12-31) — Change In Other Current Liabilities: -5418000.00
CDNA cash_flow (annual, 2023-12-31) — Change In Other Working Capital: 566000.00
CDNA cash_flow (annual, 2023-12-31) — Change In Payable: 2904000.00
CDNA cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: 93610000.00
CDNA cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: 1767000.00
CDNA cash_flow (annual, 2023-12-31) — Change In Receivables: 16016000.00
CDNA cash_flow (annual, 2023-12-31) — Change In Working Capital: 106029000.00
CDNA cash_flow (annual, 2023-12-31) — Changes In Account Receivables: 16016000.00
CDNA cash_flow (annual, 2023-12-31) — Changes In Cash: -7548000.00
CDNA balance_sheet (annual, 2023-12-31) — Common Stock: 49000.00
CDNA balance_sheet (annual, 2023-12-31) — Common Stock Equity: 261328000.00
CDNA cash_flow (annual, 2023-12-31) — Common Stock Issuance: 0.00
CDNA cash_flow (annual, 2023-12-31) — Common Stock Payments: -27541000.00
CDNA balance_sheet (annual, 2023-12-31) — Construction In Progress: 8306000.00
CDNA income_statement (annual, 2023-12-31) — Cost Of Revenue: 102066000.00
CDNA balance_sheet (annual, 2023-12-31) — Current Accrued Expenses: 28266000.00
CDNA balance_sheet (annual, 2023-12-31) — Current Assets: 313713000.00
CDNA balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 5943000.00
CDNA balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 5943000.00
CDNA balance_sheet (annual, 2023-12-31) — Current Deferred Liabilities: 5668000.00
CDNA balance_sheet (annual, 2023-12-31) — Current Deferred Revenue: 4748000.00
CDNA balance_sheet (annual, 2023-12-31) — Current Liabilities: 78072000.00
CDNA cash_flow (annual, 2023-12-31) — Deferred Income Tax: 566000.00
CDNA cash_flow (annual, 2023-12-31) — Deferred Tax: 566000.00
CDNA cash_flow (annual, 2023-12-31) — Depreciation: 19824000.00
CDNA cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 19824000.00
CDNA cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 19824000.00
CDNA balance_sheet (annual, 2023-12-31) — Derivative Product Liabilities: 0.00
CDNA income_statement (annual, 2023-12-31) — Diluted Average Shares: 53764705.00
CDNA income_statement (annual, 2023-12-31) — Diluted EPS: -3.54
CDNA income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -190284000.00
CDNA income_statement (annual, 2023-12-31) — EBIT: -107063000.00
CDNA income_statement (annual, 2023-12-31) — EBITDA: -87239000.00
CDNA cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: -112000.00
CDNA cash_flow (annual, 2023-12-31) — End Cash Position: 82783000.00
CDNA cash_flow (annual, 2023-12-31) — Financing Cash Flow: -29606000.00
CDNA balance_sheet (annual, 2023-12-31) — Finished Goods: 3658000.00
CDNA cash_flow (annual, 2023-12-31) — Free Cash Flow: -27628000.00
CDNA cash_flow (annual, 2023-12-31) — Gain Loss On Investment Securities: -294000.00
CDNA income_statement (annual, 2023-12-31) — Gain On Sale Of Security: 10000.00
CDNA balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: -6963000.00
CDNA income_statement (annual, 2023-12-31) — General And Administrative Expense: 118838000.00
CDNA balance_sheet (annual, 2023-12-31) — Goodwill: 40336000.00
CDNA balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 86037000.00
CDNA balance_sheet (annual, 2023-12-31) — Gross PPE: 97400000.00
CDNA income_statement (annual, 2023-12-31) — Gross Profit: 178258000.00
CDNA cash_flow (annual, 2023-12-31) — Income Tax Paid Supplemental Data: 738000.00
CDNA income_statement (annual, 2023-12-31) — Interest Income: 11867000.00
CDNA income_statement (annual, 2023-12-31) — Interest Income Non Operating: 11867000.00
CDNA cash_flow (annual, 2023-12-31) — Interest Paid Supplemental Data: 0.00
CDNA balance_sheet (annual, 2023-12-31) — Inventory: 19471000.00
CDNA balance_sheet (annual, 2023-12-31) — Invested Capital: 261328000.00
CDNA cash_flow (annual, 2023-12-31) — Investing Cash Flow: 40446000.00
CDNA cash_flow (annual, 2023-12-31) — Issuance Of Capital Stock: 0.00
CDNA balance_sheet (annual, 2023-12-31) — Leases: 18259000.00
CDNA balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 28278000.00
CDNA balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 28278000.00
CDNA cash_flow (annual, 2023-12-31) — Long Term Debt Payments: 0.00
CDNA balance_sheet (annual, 2023-12-31) — Machinery Furniture Equipment: 40944000.00
CDNA cash_flow (annual, 2023-12-31) — Net Business Purchase And Sale: -6682000.00
CDNA cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: -27541000.00
CDNA income_statement (annual, 2023-12-31) — Net Income: -190284000.00
CDNA income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -190284000.00
CDNA income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -190284000.00
CDNA income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -190284000.00
CDNA income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -190284000.00
CDNA cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -190284000.00
CDNA income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -190284000.00
CDNA cash_flow (annual, 2023-12-31) — Net Intangibles Purchase And Sale: -896000.00
CDNA income_statement (annual, 2023-12-31) — Net Interest Income: 11867000.00
CDNA cash_flow (annual, 2023-12-31) — Net Investment Purchase And Sale: 56368000.00
CDNA cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: 0.00
CDNA cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: 0.00
CDNA income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: 11867000.00
CDNA cash_flow (annual, 2023-12-31) — Net Other Financing Charges: -3684000.00
CDNA balance_sheet (annual, 2023-12-31) — Net PPE: 65137000.00
CDNA balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 175291000.00
CDNA balance_sheet (annual, 2023-12-31) — Non Current Deferred Liabilities: 136000.00
CDNA balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Liabilities: 136000.00
CDNA income_statement (annual, 2023-12-31) — Normalized EBITDA: 9061000.00
CDNA income_statement (annual, 2023-12-31) — Normalized Income: -114207000.00
CDNA cash_flow (annual, 2023-12-31) — Operating Cash Flow: -18388000.00
CDNA cash_flow (annual, 2023-12-31) — Operating Gains Losses: -250000.00
CDNA income_statement (annual, 2023-12-31) — Operating Income: -107063000.00
CDNA income_statement (annual, 2023-12-31) — Operating Revenue: 280324000.00
CDNA balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 51503377.00
CDNA balance_sheet (annual, 2023-12-31) — Other Current Assets: 7763000.00
CDNA balance_sheet (annual, 2023-12-31) — Other Current Liabilities: 5620000.00
CDNA balance_sheet (annual, 2023-12-31) — Other Equity Adjustments: -6963000.00
CDNA income_statement (annual, 2023-12-31) — Other Gand A: 118838000.00
CDNA income_statement (annual, 2023-12-31) — Other Income Expense: -94947000.00
CDNA balance_sheet (annual, 2023-12-31) — Other Intangible Assets: 45701000.00
CDNA cash_flow (annual, 2023-12-31) — Other Non Cash Items: 568000.00
CDNA balance_sheet (annual, 2023-12-31) — Other Non Current Assets: 1939000.00
CDNA balance_sheet (annual, 2023-12-31) — Other Non Current Liabilities: 99012000.00
CDNA income_statement (annual, 2023-12-31) — Other Non Operating Income Expenses: 1353000.00
CDNA balance_sheet (annual, 2023-12-31) — Other Properties: 29891000.00
CDNA balance_sheet (annual, 2023-12-31) — Other Short Term Investments: 153221000.00
CDNA income_statement (annual, 2023-12-31) — Other Special Charges: 96300000.00
CDNA balance_sheet (annual, 2023-12-31) — Payables: 12872000.00
CDNA balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 41138000.00
CDNA balance_sheet (annual, 2023-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 19703000.00
CDNA balance_sheet (annual, 2023-12-31) — Preferred Stock: 0.00
CDNA income_statement (annual, 2023-12-31) — Pretax Income: -190143000.00
CDNA cash_flow (annual, 2023-12-31) — Proceeds From Stock Option Exercised: 1619000.00
CDNA balance_sheet (annual, 2023-12-31) — Properties: 0.00
CDNA cash_flow (annual, 2023-12-31) — Purchase Of Business: -6682000.00
CDNA cash_flow (annual, 2023-12-31) — Purchase Of Intangibles: -896000.00
CDNA cash_flow (annual, 2023-12-31) — Purchase Of Investment: -202130000.00
CDNA balance_sheet (annual, 2023-12-31) — Raw Materials: 10622000.00
CDNA balance_sheet (annual, 2023-12-31) — Receivables: 51061000.00
CDNA income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 102066000.00
CDNA income_statement (annual, 2023-12-31) — Reconciled Depreciation: 19824000.00
CDNA cash_flow (annual, 2023-12-31) — Repayment Of Debt: 0.00
CDNA cash_flow (annual, 2023-12-31) — Repurchase Of Capital Stock: -27541000.00
CDNA income_statement (annual, 2023-12-31) — Research And Development: 82421000.00
CDNA income_statement (annual, 2023-12-31) — Restructuring And Mergern Acquisition: 2320000.00
CDNA balance_sheet (annual, 2023-12-31) — Retained Earnings: -678269000.00
CDNA cash_flow (annual, 2023-12-31) — Sale Of Investment: 258498000.00
CDNA income_statement (annual, 2023-12-31) — Selling And Marketing Expense: 84062000.00
CDNA income_statement (annual, 2023-12-31) — Selling General And Administration: 202900000.00
CDNA balance_sheet (annual, 2023-12-31) — Share Issued: 51503377.00
CDNA income_statement (annual, 2023-12-31) — Special Income Charges: -96300000.00
CDNA cash_flow (annual, 2023-12-31) — Stock Based Compensation: 49086000.00
CDNA balance_sheet (annual, 2023-12-31) — Stockholders Equity: 261328000.00
CDNA balance_sheet (annual, 2023-12-31) — Tangible Book Value: 175291000.00
CDNA income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: -20223000.00
CDNA income_statement (annual, 2023-12-31) — Tax Provision: 141000.00
CDNA income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.21
CDNA balance_sheet (annual, 2023-12-31) — Total Assets: 466826000.00
CDNA balance_sheet (annual, 2023-12-31) — Total Capitalization: 261328000.00
CDNA balance_sheet (annual, 2023-12-31) — Total Debt: 34221000.00
CDNA balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 261328000.00
CDNA income_statement (annual, 2023-12-31) — Total Expenses: 387387000.00
CDNA balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 205498000.00
CDNA balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 153113000.00
CDNA balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 127426000.00
CDNA income_statement (annual, 2023-12-31) — Total Operating Income As Reported: -203363000.00
CDNA income_statement (annual, 2023-12-31) — Total Unusual Items: -96300000.00
CDNA income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: -96300000.00
CDNA cash_flow (annual, 2023-12-31) — Unrealized Gain Loss On Investment Securities: 0.00
CDNA balance_sheet (annual, 2023-12-31) — Work In Process: 5191000.00
CDNA balance_sheet (annual, 2023-12-31) — Working Capital: 235641000.00
CDNA cash_flow (quarterly, 2024-09-30) — Asset Impairment Charge: 0.00
CDNA cash_flow (quarterly, 2024-09-30) — Change In Other Working Capital: 143000.00
CDNA cash_flow (quarterly, 2024-09-30) — Net Business Purchase And Sale: 0.00
CDNA balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 4683000.00
CDNA cash_flow (quarterly, 2024-09-30) — Purchase Of Business: 0.00
CDNA income_statement (quarterly, 2024-09-30) — Restructuring And Mergern Acquisition: 0.00
CDNA cash_flow (quarterly, 2024-09-30) — Unrealized Gain Loss On Investment Securities: 0.00
CDNA income_statement (annual, 2024-12-31) — +Operating Expense: 279624000.00
CDNA income_statement (annual, 2024-12-31) — +Total Revenue: 333785000.00
CDNA balance_sheet (annual, 2024-12-31) — Accounts Payable: 7686000.00
CDNA balance_sheet (annual, 2024-12-31) — Accounts Receivable: 64605000.00
CDNA balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -36942000.00
CDNA balance_sheet (quarterly, 2024-12-31) — Accumulated Depreciation: -36942000.00
CDNA balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 1013193000.00
CDNA cash_flow (annual, 2024-12-31) — Amortization Of Securities: 621000.00
CDNA cash_flow (annual, 2024-12-31) — Asset Impairment Charge: 0.00
CDNA cash_flow (quarterly, 2024-12-31) — Asset Impairment Charge: 0.00
CDNA income_statement (annual, 2024-12-31) — Basic Average Shares: 52773247.00
CDNA income_statement (annual, 2024-12-31) — Basic EPS: 1.00
CDNA cash_flow (annual, 2024-12-31) — Beginning Cash Position: 82783000.00
CDNA cash_flow (annual, 2024-12-31) — Capital Expenditure: -6484000.00
CDNA cash_flow (annual, 2024-12-31) — Capital Expenditure Reported: -6484000.00
CDNA cash_flow (quarterly, 2024-12-31) — Capital Expenditure Reported: -1522000.00
CDNA balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 28366000.00
CDNA balance_sheet (annual, 2024-12-31) — Capital Stock: 51000.00
CDNA balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 114689000.00
CDNA balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 260653000.00
CDNA cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: -5606000.00
CDNA cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: -483000.00
CDNA cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: 38048000.00
CDNA cash_flow (annual, 2024-12-31) — Change In Account Payable: -5110000.00
CDNA cash_flow (annual, 2024-12-31) — Change In Accrued Expense: -76994000.00
CDNA cash_flow (annual, 2024-12-31) — Change In Inventory: -1018000.00
CDNA cash_flow (annual, 2024-12-31) — Change In Other Current Liabilities: -5863000.00
CDNA cash_flow (annual, 2024-12-31) — Change In Other Working Capital: -187000.00
CDNA cash_flow (quarterly, 2024-12-31) — Change In Other Working Capital: -244000.00
CDNA cash_flow (annual, 2024-12-31) — Change In Payable: -5110000.00
CDNA cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: -82104000.00
CDNA cash_flow (annual, 2024-12-31) — Change In Prepaid Assets: 606000.00
CDNA cash_flow (annual, 2024-12-31) — Change In Receivables: -13741000.00
CDNA cash_flow (annual, 2024-12-31) — Change In Working Capital: -102120000.00
CDNA cash_flow (annual, 2024-12-31) — Changes In Account Receivables: -13741000.00
CDNA cash_flow (annual, 2024-12-31) — Changes In Cash: 31959000.00
CDNA balance_sheet (annual, 2024-12-31) — Common Stock: 51000.00
CDNA balance_sheet (annual, 2024-12-31) — Common Stock Equity: 378433000.00
CDNA cash_flow (annual, 2024-12-31) — Common Stock Payments: -522000.00
CDNA cash_flow (quarterly, 2024-12-31) — Common Stock Payments: 0.00
CDNA balance_sheet (annual, 2024-12-31) — Construction In Progress: 11937000.00
CDNA balance_sheet (quarterly, 2024-12-31) — Construction In Progress: 11937000.00
CDNA income_statement (annual, 2024-12-31) — Cost Of Revenue: 109696000.00
CDNA balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 32401000.00
CDNA balance_sheet (annual, 2024-12-31) — Current Assets: 351832000.00
CDNA balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 6103000.00
CDNA balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 6103000.00
CDNA balance_sheet (annual, 2024-12-31) — Current Deferred Liabilities: 4848000.00
CDNA balance_sheet (annual, 2024-12-31) — Current Deferred Revenue: 4848000.00
CDNA balance_sheet (annual, 2024-12-31) — Current Liabilities: 89371000.00
CDNA cash_flow (annual, 2024-12-31) — Deferred Income Tax: -187000.00
CDNA cash_flow (annual, 2024-12-31) — Deferred Tax: -187000.00
CDNA cash_flow (annual, 2024-12-31) — Depreciation: 19757000.00
CDNA cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 19757000.00
CDNA cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 19757000.00
CDNA income_statement (annual, 2024-12-31) — Diluted Average Shares: 56620590.00
CDNA income_statement (annual, 2024-12-31) — Diluted EPS: 0.93
CDNA income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: 52549000.00
CDNA income_statement (annual, 2024-12-31) — EBIT: -55535000.00
CDNA income_statement (annual, 2024-12-31) — EBITDA: -35778000.00
CDNA cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: 532000.00
CDNA cash_flow (annual, 2024-12-31) — End Cash Position: 115274000.00
CDNA cash_flow (annual, 2024-12-31) — Financing Cash Flow: -5606000.00
CDNA balance_sheet (annual, 2024-12-31) — Finished Goods: 4819000.00
CDNA cash_flow (annual, 2024-12-31) — Free Cash Flow: 31564000.00
CDNA balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: -8569000.00
CDNA income_statement (annual, 2024-12-31) — General And Administrative Expense: 125139000.00
CDNA balance_sheet (annual, 2024-12-31) — Goodwill: 40336000.00
CDNA balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 78520000.00
CDNA balance_sheet (annual, 2024-12-31) — Gross PPE: 94834000.00
CDNA income_statement (annual, 2024-12-31) — Gross Profit: 224089000.00
CDNA cash_flow (annual, 2024-12-31) — Income Tax Paid Supplemental Data: 317000.00
CDNA income_statement (annual, 2024-12-31) — Interest Income: 11765000.00
CDNA income_statement (annual, 2024-12-31) — Interest Income Non Operating: 11765000.00
CDNA cash_flow (annual, 2024-12-31) — Interest Paid Supplemental Data: 0.00
CDNA balance_sheet (annual, 2024-12-31) — Inventory: 19503000.00
CDNA balance_sheet (annual, 2024-12-31) — Invested Capital: 378433000.00
CDNA cash_flow (annual, 2024-12-31) — Investing Cash Flow: -483000.00
CDNA balance_sheet (annual, 2024-12-31) — Investments And Advances: 0.00
CDNA balance_sheet (quarterly, 2024-12-31) — Investments And Advances: 0.00
CDNA balance_sheet (annual, 2024-12-31) — Leases: 18106000.00
CDNA balance_sheet (quarterly, 2024-12-31) — Leases: 18106000.00
CDNA balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 22263000.00
CDNA balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 22263000.00
CDNA balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 40451000.00
CDNA balance_sheet (quarterly, 2024-12-31) — Machinery Furniture Equipment: 40451000.00
CDNA cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: 0.00
CDNA cash_flow (quarterly, 2024-12-31) — Net Business Purchase And Sale: 0.00
CDNA cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: -522000.00
CDNA cash_flow (quarterly, 2024-12-31) — Net Common Stock Issuance: 0.00
CDNA income_statement (annual, 2024-12-31) — Net Income: 52549000.00
CDNA income_statement (annual, 2024-12-31) — Net Income Common Stockholders: 52549000.00
CDNA income_statement (annual, 2024-12-31) — Net Income Continuous Operations: 52549000.00
CDNA income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 52549000.00
CDNA income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 52549000.00
CDNA cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: 52549000.00
CDNA income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: 52549000.00
CDNA cash_flow (annual, 2024-12-31) — Net Intangibles Purchase And Sale: 0.00
CDNA cash_flow (quarterly, 2024-12-31) — Net Intangibles Purchase And Sale: 0.00
CDNA income_statement (annual, 2024-12-31) — Net Interest Income: 11765000.00
CDNA cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: 6001000.00
CDNA income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: 11765000.00
CDNA cash_flow (annual, 2024-12-31) — Net Other Financing Charges: -15417000.00
CDNA balance_sheet (annual, 2024-12-31) — Net PPE: 57892000.00
CDNA balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 299913000.00
CDNA balance_sheet (annual, 2024-12-31) — Non Current Deferred Liabilities: 164000.00
CDNA balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Liabilities: 164000.00
CDNA income_statement (annual, 2024-12-31) — Normalized EBITDA: -132078000.00
CDNA income_statement (annual, 2024-12-31) — Normalized Income: -43173200.00
CDNA cash_flow (annual, 2024-12-31) — Operating Cash Flow: 38048000.00
CDNA cash_flow (annual, 2024-12-31) — Operating Gains Losses: 91000.00
CDNA income_statement (annual, 2024-12-31) — Operating Income: -55535000.00
CDNA income_statement (annual, 2024-12-31) — Operating Revenue: 333785000.00
CDNA balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 54771203.00
CDNA balance_sheet (annual, 2024-12-31) — Other Current Assets: 7071000.00
CDNA balance_sheet (annual, 2024-12-31) — Other Current Liabilities: 2540000.00
CDNA balance_sheet (quarterly, 2024-12-31) — Other Current Liabilities: 2540000.00
CDNA balance_sheet (annual, 2024-12-31) — Other Equity Adjustments: -8569000.00
CDNA income_statement (annual, 2024-12-31) — Other Gand A: 125139000.00
CDNA income_statement (annual, 2024-12-31) — Other Income Expense: 96629000.00
CDNA balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 38184000.00
CDNA balance_sheet (annual, 2024-12-31) — Other Investments: 0.00
CDNA balance_sheet (quarterly, 2024-12-31) — Other Investments: 0.00
CDNA cash_flow (annual, 2024-12-31) — Other Non Cash Items: 931000.00
CDNA balance_sheet (annual, 2024-12-31) — Other Non Current Assets: 2806000.00
CDNA balance_sheet (annual, 2024-12-31) — Other Non Current Liabilities: 819000.00
CDNA income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: 329000.00
CDNA balance_sheet (annual, 2024-12-31) — Other Properties: 24340000.00
CDNA balance_sheet (annual, 2024-12-31) — Other Short Term Investments: 145964000.00
CDNA income_statement (annual, 2024-12-31) — Other Special Charges: -96300000.00
CDNA balance_sheet (annual, 2024-12-31) — Payables: 7686000.00
CDNA balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 40087000.00
CDNA balance_sheet (annual, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 38333000.00
CDNA balance_sheet (annual, 2024-12-31) — Preferred Stock: 0.00
CDNA income_statement (annual, 2024-12-31) — Pretax Income: 52859000.00
CDNA cash_flow (annual, 2024-12-31) — Proceeds From Stock Option Exercised: 10333000.00
CDNA balance_sheet (annual, 2024-12-31) — Properties: 0.00
CDNA balance_sheet (quarterly, 2024-12-31) — Properties: 0.00
CDNA cash_flow (annual, 2024-12-31) — Purchase Of Business: 0.00
CDNA cash_flow (quarterly, 2024-12-31) — Purchase Of Business: 0.00
CDNA cash_flow (annual, 2024-12-31) — Purchase Of Intangibles: 0.00
CDNA cash_flow (quarterly, 2024-12-31) — Purchase Of Intangibles: 0.00
CDNA cash_flow (annual, 2024-12-31) — Purchase Of Investment: -160920000.00
CDNA balance_sheet (annual, 2024-12-31) — Raw Materials: 10891000.00
CDNA balance_sheet (annual, 2024-12-31) — Receivables: 64605000.00
CDNA income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 109696000.00
CDNA income_statement (annual, 2024-12-31) — Reconciled Depreciation: 19757000.00
CDNA cash_flow (annual, 2024-12-31) — Repurchase Of Capital Stock: -522000.00
CDNA cash_flow (quarterly, 2024-12-31) — Repurchase Of Capital Stock: 0.00
CDNA income_statement (annual, 2024-12-31) — Research And Development: 72510000.00
CDNA income_statement (annual, 2024-12-31) — Restructuring And Mergern Acquisition: 1783000.00
CDNA income_statement (quarterly, 2024-12-31) — Restructuring And Mergern Acquisition: 1715000.00
CDNA balance_sheet (annual, 2024-12-31) — Retained Earnings: -626242000.00
CDNA cash_flow (annual, 2024-12-31) — Sale Of Investment: 166921000.00
CDNA income_statement (annual, 2024-12-31) — Selling And Marketing Expense: 81975000.00
CDNA income_statement (annual, 2024-12-31) — Selling General And Administration: 207114000.00
CDNA balance_sheet (annual, 2024-12-31) — Share Issued: 54771203.00
CDNA income_statement (annual, 2024-12-31) — Special Income Charges: 96300000.00
CDNA cash_flow (annual, 2024-12-31) — Stock Based Compensation: 66406000.00
CDNA balance_sheet (annual, 2024-12-31) — Stockholders Equity: 378433000.00
CDNA balance_sheet (annual, 2024-12-31) — Tangible Book Value: 299913000.00
CDNA income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: 577800.00
CDNA income_statement (annual, 2024-12-31) — Tax Provision: 310000.00
CDNA income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.01
CDNA balance_sheet (annual, 2024-12-31) — Total Assets: 491050000.00
CDNA balance_sheet (annual, 2024-12-31) — Total Capitalization: 378433000.00
CDNA balance_sheet (annual, 2024-12-31) — Total Debt: 28366000.00
CDNA balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 378433000.00
CDNA income_statement (annual, 2024-12-31) — Total Expenses: 389320000.00
CDNA balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 112617000.00
CDNA balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 139218000.00
CDNA balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 23246000.00
CDNA income_statement (annual, 2024-12-31) — Total Operating Income As Reported: 40765000.00
CDNA income_statement (annual, 2024-12-31) — Total Unusual Items: 96300000.00
CDNA income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: 96300000.00
CDNA cash_flow (annual, 2024-12-31) — Unrealized Gain Loss On Investment Securities: 0.00
CDNA cash_flow (quarterly, 2024-12-31) — Unrealized Gain Loss On Investment Securities: 0.00
CDNA balance_sheet (annual, 2024-12-31) — Work In Process: 3793000.00
CDNA balance_sheet (annual, 2024-12-31) — Working Capital: 262461000.00
CDNA income_statement (quarterly, 2025-03-31) — +Operating Expense: 64284000.00
CDNA income_statement (quarterly, 2025-03-31) — +Total Revenue: 84685000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 8072000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 71485000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 1022982000.00
CDNA cash_flow (quarterly, 2025-03-31) — Amortization Of Securities: 837000.00
CDNA income_statement (quarterly, 2025-03-31) — Basic Average Shares: 55262459.00
CDNA income_statement (quarterly, 2025-03-31) — Basic EPS: -0.19
CDNA cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 115274000.00
CDNA cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -1630000.00
CDNA cash_flow (quarterly, 2025-03-31) — Capital Expenditure Reported: -1630000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 30277000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Capital Stock: 51000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 88745000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 230917000.00
CDNA cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: -643000.00
CDNA cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: 1325000.00
CDNA cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: -26584000.00
CDNA cash_flow (quarterly, 2025-03-31) — Change In Account Payable: 377000.00
CDNA cash_flow (quarterly, 2025-03-31) — Change In Accrued Expense: -17774000.00
CDNA cash_flow (quarterly, 2025-03-31) — Change In Inventory: -2674000.00
CDNA cash_flow (quarterly, 2025-03-31) — Change In Other Current Liabilities: -1483000.00
CDNA cash_flow (quarterly, 2025-03-31) — Change In Payable: 377000.00
CDNA cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: -17397000.00
CDNA cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: -2784000.00
CDNA cash_flow (quarterly, 2025-03-31) — Change In Receivables: -6640000.00
CDNA cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -30978000.00
CDNA cash_flow (quarterly, 2025-03-31) — Changes In Account Receivables: -6640000.00
CDNA cash_flow (quarterly, 2025-03-31) — Changes In Cash: -25902000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Common Stock: 51000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 379349000.00
CDNA cash_flow (quarterly, 2025-03-31) — Common Stock Payments: 0.00
CDNA income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 28415000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 50308000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Current Assets: 350239000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 6205000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 6205000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Current Deferred Liabilities: 5672000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Current Deferred Revenue: 5422000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 85284000.00
CDNA cash_flow (quarterly, 2025-03-31) — Depreciation: 4940000.00
CDNA cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 4940000.00
CDNA cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 4940000.00
CDNA income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 55262459.00
CDNA income_statement (quarterly, 2025-03-31) — Diluted EPS: -0.19
CDNA income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -10353000.00
CDNA income_statement (quarterly, 2025-03-31) — EBIT: -8014000.00
CDNA income_statement (quarterly, 2025-03-31) — EBITDA: -3074000.00
CDNA cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: -77000.00
CDNA cash_flow (quarterly, 2025-03-31) — End Cash Position: 89295000.00
CDNA cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: -643000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Finished Goods: 4420000.00
CDNA cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -28214000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: -7089000.00
CDNA income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 22769000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Goodwill: 40336000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 77583000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Gross PPE: 59119000.00
CDNA income_statement (quarterly, 2025-03-31) — Gross Profit: 56270000.00
CDNA income_statement (quarterly, 2025-03-31) — Interest Income: 2784000.00
CDNA income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 2784000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Inventory: 22929000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Invested Capital: 379349000.00
CDNA cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: 1325000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 24072000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 24072000.00
CDNA cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: 0.00
CDNA income_statement (quarterly, 2025-03-31) — Net Income: -10353000.00
CDNA income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -10353000.00
CDNA income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -10353000.00
CDNA income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -10353000.00
CDNA income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -10353000.00
CDNA cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -10353000.00
CDNA income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -10353000.00
CDNA income_statement (quarterly, 2025-03-31) — Net Interest Income: 2784000.00
CDNA cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: 2955000.00
CDNA income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 2784000.00
CDNA cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: -4565000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Net PPE: 59119000.00
CDNA cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -1630000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 301766000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Liabilities: 129000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 129000.00
CDNA income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 2286000.00
CDNA income_statement (quarterly, 2025-03-31) — Normalized Income: -6118600.00
CDNA cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -26584000.00
CDNA income_statement (quarterly, 2025-03-31) — Operating Income: -8014000.00
CDNA income_statement (quarterly, 2025-03-31) — Operating Revenue: 84685000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 55462730.00
CDNA balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 24908000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 960000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: -7089000.00
CDNA income_statement (quarterly, 2025-03-31) — Other Gand A: 22769000.00
CDNA income_statement (quarterly, 2025-03-31) — Other Income Expense: -5065000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 37247000.00
CDNA cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 39000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 2697000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 804000.00
CDNA income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 295000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Other Properties: 59119000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 142172000.00
CDNA income_statement (quarterly, 2025-03-31) — Other Special Charges: 5360000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Payables: 8072000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 58380000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 14067000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Preferred Stock: 0.00
CDNA income_statement (quarterly, 2025-03-31) — Pretax Income: -10295000.00
CDNA cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 3922000.00
CDNA cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: -52472000.00
CDNA cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -1630000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Raw Materials: 13703000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Receivables: 71485000.00
CDNA income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 28415000.00
CDNA income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 4940000.00
CDNA cash_flow (quarterly, 2025-03-31) — Repurchase Of Capital Stock: 0.00
CDNA income_statement (quarterly, 2025-03-31) — Research And Development: 18524000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -636595000.00
CDNA cash_flow (quarterly, 2025-03-31) — Sale Of Investment: 55427000.00
CDNA income_statement (quarterly, 2025-03-31) — Selling And Marketing Expense: 22991000.00
CDNA income_statement (quarterly, 2025-03-31) — Selling General And Administration: 45760000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Share Issued: 55462730.00
CDNA income_statement (quarterly, 2025-03-31) — Special Income Charges: -5360000.00
CDNA cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 8931000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 379349000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 301766000.00
CDNA income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: -1125600.00
CDNA income_statement (quarterly, 2025-03-31) — Tax Provision: 58000.00
CDNA income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.21
CDNA balance_sheet (quarterly, 2025-03-31) — Total Assets: 489638000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 379349000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Total Debt: 30277000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 379349000.00
CDNA income_statement (quarterly, 2025-03-31) — Total Expenses: 92699000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 110289000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 139399000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 25005000.00
CDNA income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: -13374000.00
CDNA income_statement (quarterly, 2025-03-31) — Total Unusual Items: -5360000.00
CDNA income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: -5360000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Work In Process: 4806000.00
CDNA balance_sheet (quarterly, 2025-03-31) — Working Capital: 264955000.00
CDNA income_statement (quarterly, 2025-06-30) — +Operating Expense: 68792000.00
CDNA income_statement (quarterly, 2025-06-30) — +Total Revenue: 86679000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 9863000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 67362000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 1028591000.00
CDNA cash_flow (quarterly, 2025-06-30) — Amortization Of Securities: -275000.00
CDNA income_statement (quarterly, 2025-06-30) — Basic Average Shares: 54304754.00
CDNA income_statement (quarterly, 2025-06-30) — Basic EPS: -0.16
CDNA cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 89295000.00
CDNA cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -1007000.00
CDNA cash_flow (quarterly, 2025-06-30) — Capital Expenditure Reported: -1007000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 29122000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Capital Stock: 53000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 68212000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 186255000.00
CDNA cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: -53811000.00
CDNA cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: 23397000.00
CDNA cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: 9895000.00
CDNA cash_flow (quarterly, 2025-06-30) — Change In Account Payable: 1248000.00
CDNA cash_flow (quarterly, 2025-06-30) — Change In Accrued Expense: 4015000.00
CDNA cash_flow (quarterly, 2025-06-30) — Change In Inventory: -4067000.00
CDNA cash_flow (quarterly, 2025-06-30) — Change In Other Current Liabilities: -1470000.00
CDNA cash_flow (quarterly, 2025-06-30) — Change In Payable: 1248000.00
CDNA cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: 5263000.00
CDNA cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: -1386000.00
CDNA cash_flow (quarterly, 2025-06-30) — Change In Receivables: 4304000.00
CDNA cash_flow (quarterly, 2025-06-30) — Change In Working Capital: 3760000.00
CDNA cash_flow (quarterly, 2025-06-30) — Changes In Account Receivables: 4304000.00
CDNA cash_flow (quarterly, 2025-06-30) — Changes In Cash: -20519000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Common Stock: 53000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 327370000.00
CDNA cash_flow (quarterly, 2025-06-30) — Common Stock Payments: -50000000.00
CDNA income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 28658000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 51967000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Current Assets: 307296000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 6342000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 6342000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Current Deferred Liabilities: 5952000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Current Deferred Revenue: 5952000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 93180000.00
CDNA cash_flow (quarterly, 2025-06-30) — Depreciation: 5053000.00
CDNA cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 5053000.00
CDNA cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 5053000.00
CDNA income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 54304754.00
CDNA income_statement (quarterly, 2025-06-30) — Diluted EPS: -0.16
CDNA income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -8568000.00
CDNA income_statement (quarterly, 2025-06-30) — EBIT: -10771000.00
CDNA income_statement (quarterly, 2025-06-30) — EBITDA: -5718000.00
CDNA cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: -13000.00
CDNA cash_flow (quarterly, 2025-06-30) — End Cash Position: 68763000.00
CDNA cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: -53811000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Finished Goods: 8396000.00
CDNA cash_flow (quarterly, 2025-06-30) — Free Cash Flow: 8888000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: -6113000.00
CDNA income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 27683000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Goodwill: 40336000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 76373000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Gross PPE: 57306000.00
CDNA income_statement (quarterly, 2025-06-30) — Gross Profit: 58021000.00
CDNA income_statement (quarterly, 2025-06-30) — Interest Income: 2364000.00
CDNA income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 2364000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Inventory: 27915000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Invested Capital: 327370000.00
CDNA cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: 23397000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 22780000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 22780000.00
CDNA cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: -50000000.00
CDNA income_statement (quarterly, 2025-06-30) — Net Income: -8568000.00
CDNA income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -8568000.00
CDNA income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -8568000.00
CDNA income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -8568000.00
CDNA income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -8568000.00
CDNA cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: -8568000.00
CDNA income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -8568000.00
CDNA income_statement (quarterly, 2025-06-30) — Net Interest Income: 2364000.00
CDNA cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: 24404000.00
CDNA income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: 2364000.00
CDNA cash_flow (quarterly, 2025-06-30) — Net Other Financing Charges: -6239000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Net PPE: 57306000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 250997000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Liabilities: 131000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Liabilities: 131000.00
CDNA income_statement (quarterly, 2025-06-30) — Normalized EBITDA: -5368000.00
CDNA income_statement (quarterly, 2025-06-30) — Normalized Income: -8222715.03
CDNA cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: 9895000.00
CDNA income_statement (quarterly, 2025-06-30) — Operating Income: -10771000.00
CDNA income_statement (quarterly, 2025-06-30) — Operating Revenue: 86679000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 53220123.00
CDNA balance_sheet (quarterly, 2025-06-30) — Other Current Assets: 25764000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: -6113000.00
CDNA income_statement (quarterly, 2025-06-30) — Other Gand A: 27683000.00
CDNA income_statement (quarterly, 2025-06-30) — Other Income Expense: -278000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Other Intangible Assets: 36037000.00
CDNA cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: 501000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 3282000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Other Non Current Liabilities: 796000.00
CDNA income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 72000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Other Properties: 57306000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Other Short Term Investments: 118043000.00
CDNA income_statement (quarterly, 2025-06-30) — Other Special Charges: 350000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Payables: 9863000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 61830000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Pensionand Other Post Retirement Benefit Plans Current: 19056000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Preferred Stock: 0.00
CDNA income_statement (quarterly, 2025-06-30) — Pretax Income: -8685000.00
CDNA cash_flow (quarterly, 2025-06-30) — Proceeds From Stock Option Exercised: 2428000.00
CDNA cash_flow (quarterly, 2025-06-30) — Purchase Of Investment: -14808000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Raw Materials: 13869000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Receivables: 67362000.00
CDNA income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 28658000.00
CDNA income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 5053000.00
CDNA cash_flow (quarterly, 2025-06-30) — Repurchase Of Capital Stock: -50000000.00
CDNA income_statement (quarterly, 2025-06-30) — Research And Development: 16830000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -695161000.00
CDNA cash_flow (quarterly, 2025-06-30) — Sale Of Investment: 39212000.00
CDNA income_statement (quarterly, 2025-06-30) — Selling And Marketing Expense: 24279000.00
CDNA income_statement (quarterly, 2025-06-30) — Selling General And Administration: 51962000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Share Issued: 53220123.00
CDNA income_statement (quarterly, 2025-06-30) — Special Income Charges: -350000.00
CDNA cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 9424000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 327370000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 250997000.00
CDNA income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: -4715.03
CDNA income_statement (quarterly, 2025-06-30) — Tax Provision: -117000.00
CDNA income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.01
CDNA balance_sheet (quarterly, 2025-06-30) — Total Assets: 444257000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 327370000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Total Debt: 29122000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 327370000.00
CDNA income_statement (quarterly, 2025-06-30) — Total Expenses: 97450000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 116887000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 136961000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 23707000.00
CDNA income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: -11121000.00
CDNA income_statement (quarterly, 2025-06-30) — Total Unusual Items: -350000.00
CDNA income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: -350000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Work In Process: 5650000.00
CDNA balance_sheet (quarterly, 2025-06-30) — Working Capital: 214116000.00